This study is undertaken to evaluate the toxicity and obtain preliminary evidence of the efficacy of the combination of ziduvodine and interleukin 2 in the treatment of HIV infection. This study is designed as a dose escalation study. Groups of three to five patients are enrolled on a given dose of IL-2 starting at a .25 million units per day. The IL-2 is administered for three weeks by continuous infusion. The goal of this study is to determine the maximum tolerated dose of the combination of IL-2 and AZT. To date, 23 patients have enrolled in the study, receiving up to 4 million units of IL-2 per day. Toxicities that have been seen to date include renal dysfunction, respiratory distress, hepatitis, and severe myelgias/fatigue. Immunostimulatory effects of IL-2 have been seen at doses above l million units/d, and have included increases in CD4 counts, natural killer cell activity, lymphokine-activated killer cell (LAK cell) number and LAK cell activity. Responses to date appear to be temporary, however, and have largely disappeared by one month after discontinuation of IL-2. Current plans are to treat a small number of patients with IL-2 administered for 5 days every 2 months for 1 year, to determine the long- term toxicible and potential benefit of IL-2 in HIV-infected patients. The importance of this study is that it assesses a combination of an antiviral drug and an immunostimulatory drug in one of the first trials of its kind in the U.S.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL000036-04
Application #
3853018
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Porter, Brian O; Anthony, Kara B; Shen, Jean et al. (2009) Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS 23:203-12
Porter, Brian O; Shen, Jean; Kovacs, Joseph A et al. (2009) Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 23:2015-9
Read, Sarah W; Lempicki, Richard A; Di Mascio, Michele et al. (2008) CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis 198:843-50
Healey, Letha M; Hahn, Barbara K; Rehm, Catherine A et al. (2008) The effect of continuous versus pericycle antiretroviral therapy on IL-2 responsiveness. J Interferon Cytokine Res 28:455-62
Morse, Caryn G; Kovacs, Joseph A (2008) HIV-infected immunologic non-responders: can we provide a helping hand? Enferm Infecc Microbiol Clin 26:1-3
Sereti, Irini; Sklar, Peter; Ramchandani, Meena S et al. (2007) CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis 196:677-83
Sereti, Irini; Anthony, Kara B; Martinez-Wilson, Hector et al. (2004) IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104:775-80
Farel, Claire E; Chaitt, Doreen G; Hahn, Barbara K et al. (2004) Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 103:3282-6
Lu, Amy C; Jones, Elizabeth C; Chow, Catherine et al. (2003) Increases in CD4+ T lymphocytes occur without increases in thymic size in HIV-infected subjects receiving interleukin-2 therapy. J Acquir Immune Defic Syndr 34:299-303
Natarajan, Ven; Lempicki, Richard A; Sereti, Irini et al. (2002) Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci U S A 99:10712-7

Showing the most recent 10 out of 20 publications